| Date | Title | Description | Source |
| 14.03.2024 | Pharming Group reports fourth quarter and full year 2023 fin... | - | globenewsw... |
| 09.08.2023 | Pharming announces first patient enrolled in Phase III clini... | Single-arm Phase III study in Japan evaluating leniolisib in patients aged 12 years and older with A... | en.prnasia... |
| 11.04.2023 | Pharming announces the first commercial shipments of Joenja®... | LEIDEN, Netherlands, April 11, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euro... | en.prnasia... |
| 25.03.2023 | Pharming announces US FDA approval of Joenja® (leniolisib) a... | APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary ... | en.prnasia... |
| 24.03.2023 | Pharming announces US FDA approval of Joenja® (leniolisib) a... | APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary ... | einpresswi... |
| 21.02.2023 | Pharming announces first patient enrolled in pediatric clini... | The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years wi... | en.prnasia... |
| 16.02.2023 | Pharming provides update on EMA regulatory review of lenioli... | EMA Marketing Authorisation Application for leniolisib changed to standard review timetable
LEIDEN, ... | en.prnasia... |
| 15.12.2022 | Pharming announces positive interim analysis data from open-... | V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who ... | en.prnasia... |
| 07.12.2022 | Pharming announces publication of data from Phase 3 Study of... | Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary... | en.prnasia... |
| 28.10.2022 | Pharming Announces European Medicines Agency (EMA) Validates... | Marketing authorisation in the European Economic Area anticipated in H1 2023
LEIDEN, Netherlands, Oc... | en.prnasia... |
| 11.10.2022 | Pharming submits a Marketing Authorisation Application to th... | Application is based on randomized, controlled and long-term extension data for leniolisib as a trea... | en.prnasia... |
| 28.09.2022 | Pharming Announces US FDA Acceptance for Priority Review of ... | The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-... | en.prnasia... |
| 02.08.2022 | Pharming Announces New ICD-10-CM Code for APDS, a Rare Prima... | Implemented by the Centers for Disease Control and Prevention, the diagnosis code will accurately id... | en.prnasia... |
| 01.08.2022 | Pharming Group Receives Accelerated Assessment in Europe for... | EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to... | en.prnasia... |
| 01.04.2022 | Pharming Announces Positive Data from Phase II/III Leniolisi... | LEIDEN, Netherlands, April 1, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or &quo... | en.prnasia... |
| 02.02.2022 | 4SC pulls plug on domatinostat; Pharming says leniolisib mee... | The management board of 4SC has discontinued its domatinostat program after the most recent clinical... | endpts.com... |
| 14.09.2021 | Pharming N : announces results from clinical trials for the ... | Pharming announces results from clinical trials for the treatment of
COVID-19 with RUCONEST®
Pharmin... | marketscre... |
| 20.07.2021 | Pharming N : signs agreement with NewBridge Pharmaceuticals ... | Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in th... | marketscre... |
| 23.06.2021 | Pharming N : announces completion of enrolment in Phase II/I... | Pharming announces the successful completion of patient enrolment in the pivotal Phase II/III triple... | marketscre... |
| 04.06.2021 | PHARMING GROUP N.V.
Pharming N : announces the reimbursemen... | Pharming Group announces that an agreement has been reached with the Spanish Ministry of Health to g... | marketscre... |
| 01.06.2021 | PHARMING GROUP N.V.
Pharming N : Group to present at Jeffer... | Pharming Group announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jeff... | marketscre... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Figh... | Alain Mérieux, founder of BioMérieux.AFP via Getty Images | forbes.com... |
| 13.03.2020 | CureVac’s Ingmar Hoerr tells us why he returned to take... | Ingmar Hoerr
On Tuesday, Ingmar Hoerr stood up from his seat at the head of CureVac’s board ... | endpts.com... |
| 19.09.2018 | UK advises against covering Novartis' Kymriah for ad... | → Right on the heels of endorsing the use of Novartis’ CAR-T Kymriah in children, the UK drug... | endpts.com... |
| 09.08.2005 | Pharming gets Japanese patent on human lactoferrin | The patent covers the production and purification of the lactoferrin using the Pharming's technology... | foodnaviga... |
| 14.07.2005 | Pharming announces research collaboration with Novathera | Pharming announces research collaboration with Novathera
14-07-2005
Leiden, The Netherlands, July 12... | cambridgen... |
